Palatin Technologies, Inc. (PTN) News
Filter PTN News Items
PTN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTN News Highlights
- For PTN, its 30 day story count is now at 5.
- Over the past 6 days, the trend for PTN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- BIO and KRON are the most mentioned tickers in articles about PTN.
Latest PTN News From Around the Web
Below are the latest news stories about PALATIN TECHNOLOGIES INC that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Palatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call TranscriptPalatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call Transcript November 14, 2023 Operator: Greetings. Welcome to Palatin’s First Quarter Fiscal Year 2024 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. Before […] |
Q1 2024 Palatin Technologies Inc Earnings CallQ1 2024 Palatin Technologies Inc Earnings Call |
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal first quarter ended September 30, 2023, and provided a corporate update. |
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue EstimatesKronos Bio, Inc. (KRON) delivered earnings and revenue surprises of -5.88% and 63.32%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets. |
Palatin Announces Closing of $5 Million Registered Direct OfferingPalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common stock (or common stock equivalents in lieu thereof). Pal |
Palatin Announces $5 Million Registered Direct OfferingPalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an aggregate of 2,358,491 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $2.12 per share of common st |
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue ResultsPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced preliminary fiscal year 2024 first quarter ended September 30, 2023 results, for Vyleesi® product revenue. Vyleesi is the first and only as-needed treatment approved by the U.S. Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire |
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese PatientsPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024. In addition, Palati |
Palatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis TreatmentPalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of a poster entitled Cellular and Molecular Impact of the Melanocortin Receptor Agonist PL8177 in DSS Induced Colitis in Rats at the United European Gastroenterology Week (UEG) being held October 14-17 2023 in Copenhagen, Denmark. Lead author Paul S. Kayne, Ph.D., Vice P |